Skip to main content
Fig. 4 | Clinical and Translational Allergy

Fig. 4

From: Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis

Fig. 4

Proportion of patients achieving the complete/near-to-complete response after treatment with rupatadine 10 mg or 20 mg for T4NSS and T6SS. Data are expressed as percentage of patients achieving the complete/near-to-complete endpoints: a complete/near-to-complete reduction was defined as T4NSS score ≤ 2 and each symptom score ≤ 1, b complete/near-to-complete reduction was defined as T6SS score ≤ 3 and each symptom score ≤ 1. Statistical significance was calculated with the Mann–Whitney test. ***p < 0.001; **p < 0.01 (rupatadine groups vs placebo); ‡p < 0.05 (rupatadine 10 mg vs rupatadine 20 mg)

Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us